Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Mogg

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Statistics in Medicine|April 21, 2006
Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal dataRobin Mogg, Devan V Mehrotra
Biometrics|November 9, 2011
Evaluating correlation-based metric for surrogate marker qualification within a causal correlation frameworkYue Wang, Robin Mogg, Jared Lunceford
Contemporary Clinical Trials Communications|June 30, 2023
A template for the authoring of statistical analysis plansGary Stevens, Shawn Dolley, Robin Mogg, et al.
Statistics in Medicine|July 18, 2009
Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?Guanghan F Liu, Kaifeng Lu, Robin Mogg, et al.
Journal of Biopharmaceutical Statistics|August 19, 2003
Monitoring the stability of human vaccinesWilliam R Fairweather, Robin Mogg, Philip S Bennett, et al.
Journal of Pharmaceutical Sciences|March 14, 2009
Measurement and decomposition kinetics of residual hydrogen peroxide in the presence of commonly used excipients and preservativesVictoria Towne, C Brent Oswald, Robin Mogg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 8, 2008
HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccineErin K Quirk, Robin Mogg, Deborah D Brown, et al.
Clinical Trials (London, England)|January 16, 2016
Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challengesAn Vandebosch, Robin Mogg, Nele Goeyvaerts, et al.
Biomarkers in Medicine|May 26, 2021
Perspectives on statistical strategies for the regulatory biomarker qualification processSuzanne B Hendrix, Robin Mogg, Sue Jane Wang, et al.
Open Forum Infectious Diseases|March 4, 2015
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without AdjuvantsErin K Quirk, Elizabeth L Brown, Randi Y Leavitt, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Statistics in Medicine|April 21, 2006
Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal dataRobin Mogg, Devan V Mehrotra
Biometrics|November 9, 2011
Evaluating correlation-based metric for surrogate marker qualification within a causal correlation frameworkYue Wang, Robin Mogg, Jared Lunceford
Contemporary Clinical Trials Communications|June 30, 2023
A template for the authoring of statistical analysis plansGary Stevens, Shawn Dolley, Robin Mogg, et al.
Statistics in Medicine|July 18, 2009
Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?Guanghan F Liu, Kaifeng Lu, Robin Mogg, et al.
Journal of Biopharmaceutical Statistics|August 19, 2003
Monitoring the stability of human vaccinesWilliam R Fairweather, Robin Mogg, Philip S Bennett, et al.
Journal of Pharmaceutical Sciences|March 14, 2009
Measurement and decomposition kinetics of residual hydrogen peroxide in the presence of commonly used excipients and preservativesVictoria Towne, C Brent Oswald, Robin Mogg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 8, 2008
HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccineErin K Quirk, Robin Mogg, Deborah D Brown, et al.
Clinical Trials (London, England)|January 16, 2016
Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challengesAn Vandebosch, Robin Mogg, Nele Goeyvaerts, et al.
Biomarkers in Medicine|May 26, 2021
Perspectives on statistical strategies for the regulatory biomarker qualification processSuzanne B Hendrix, Robin Mogg, Sue Jane Wang, et al.
Open Forum Infectious Diseases|March 4, 2015
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without AdjuvantsErin K Quirk, Elizabeth L Brown, Randi Y Leavitt, et al.
Pageof 4